Alumis Inc
Clinical trials sponsored by Alumis Inc, explained in plain language.
-
Psoriasis drug ESK-001 put to the test in Long-Term safety study
Disease control OngoingThis study is checking the long-term safety and effectiveness of the drug ESK-001 (envudeucitinib) for people with plaque psoriasis. It includes 165 adults who have already completed a previous ESK-001 study. Participants will take the drug as an oral tablet and be monitored for …
Phase: PHASE2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New psoriasis drug shows promise in Long-Term trial
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug ESK-001 for people with moderate to severe plaque psoriasis. Participants are adults who have already completed a prior ESK-001 study. They will take ESK-001 twice daily for 24 weeks, and some may later switch…
Phase: PHASE3 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New lupus pill shows promise in Mid-Stage trial
Disease control OngoingThis Phase 2 study tests an experimental oral drug called ESK-001 in 408 adults with active systemic lupus erythematosus (SLE). Participants receive either ESK-001 or a placebo for 48 weeks to see if the drug can reduce disease activity. The goal is to find a new treatment option…
Phase: PHASE2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC